DYNAVAX TECHNOLOGIES CORP (DVAX)
US2681582019 - Common Stock
Overall DVAX gets a fundamental rating of 5 out of 10. We evaluated DVAX against 588 industry peers in the Biotechnology industry. While DVAX has a great health rating, its profitability is only average at the moment. DVAX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
DVAX had negative earnings in the past year.
DVAX had a positive operating cash flow in the past year.
In multiple years DVAX reported negative net income over the last 5 years.
In multiple years DVAX reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DVAX (-0.64%) is better than 93.85% of its industry peers.
With an excellent Return On Equity value of -1.03%, DVAX belongs to the best of the industry, outperforming 93.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.64% | ||
| ROE | -1.03% | ||
| ROIC | N/A |
ROA(3y)12%
ROA(5y)-8.23%
ROE(3y)27.27%
ROE(5y)-384.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Gross Margin of 78.43% is amongst the best of the industry. DVAX outperforms 86.50% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
DVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been increased compared to 1 year ago.
Compared to 5 years ago, DVAX has more shares outstanding
DVAX has a better debt/assets ratio than last year.
2.2 Solvency
DVAX has an Altman-Z score of 2.16. This is not the best score and indicates that DVAX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of DVAX (2.16) is better than 71.79% of its industry peers.
The Debt to FCF ratio of DVAX is 2.31, which is a good value as it means it would take DVAX, 2.31 years of fcf income to pay off all of its debts.
DVAX has a better Debt to FCF ratio (2.31) than 95.73% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that DVAX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.36, DVAX is doing worse than 71.28% of the companies in the same industry.
Although DVAX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.31 | ||
| Altman-Z | 2.16 |
ROIC/WACCN/A
WACC8.29%
2.3 Liquidity
A Current Ratio of 13.81 indicates that DVAX has no problem at all paying its short term obligations.
DVAX's Current ratio of 13.81 is amongst the best of the industry. DVAX outperforms 88.89% of its industry peers.
A Quick Ratio of 12.96 indicates that DVAX has no problem at all paying its short term obligations.
The Quick ratio of DVAX (12.96) is better than 86.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.96 |
3. Growth
3.1 Past
DVAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -103.05%.
The Revenue for DVAX has decreased by -67.87% in the past year. This is quite bad
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 95.18% on average per year.
EPS 1Y (TTM)-103.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-100%
Revenue 1Y (TTM)-67.87%
Revenue growth 3Y70.82%
Revenue growth 5Y95.18%
Revenue growth Q2Q-69.87%
3.2 Future
Based on estimates for the next years, DVAX will show a very strong growth in Earnings Per Share. The EPS will grow by 136.45% on average per year.
The Revenue is expected to grow by 23.16% on average over the next years. This is a very strong growth
EPS Next Y538.6%
EPS Next 2Y225.5%
EPS Next 3Y136.45%
EPS Next 5YN/A
Revenue Next Year25.52%
Revenue Next 2Y23.05%
Revenue Next 3Y21.5%
Revenue Next 5Y23.16%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 43.09, the valuation of DVAX can be described as expensive.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.27, DVAX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.09 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DVAX is valued cheaply inside the industry as 97.78% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.35 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DVAX's earnings are expected to grow with 136.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y225.5%
EPS Next 3Y136.45%
5. Dividend
5.1 Amount
No dividends for DVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DYNAVAX TECHNOLOGIES CORP
NASDAQ:DVAX (4/18/2024, 7:00:02 PM)
After market: 11.34 0 (0%)11.34
-0.09 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.48B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.09 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.64% | ||
| ROE | -1.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.43% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-103.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y538.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.87%
Revenue growth 3Y70.82%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y